METHODS FOR CORRECTING CYTOSTATIC DISEASE IN PATIENTS WITH RHEUMATOID POLYARTHRITIS DURING METHOTREXATE THERAPY

Аннотация

Methotrexate is widely used as a first-line disease-modifying agent in the treatment of rheumatoid polyarthritis; however, its administration is often complicated by cytostatic disease, including leukopenia, hepatotoxicity, mucositis, and gastrointestinal intolerance. These side effects can lead to dose reduction or discontinuation, ultimately reducing treatment efficacy and increasing disease activity. This study evaluated the effectiveness of an integrated correction strategy involving folinic acid, hepatoprotective therapy, and hematopoietic stimulants in managing methotrexate-induced cytostatic complications. A total of 60 patients were enrolled and observed over 12 weeks. The integrated approach significantly improved clinical symptoms, normalised laboratory values more rapidly, and reduced the need for methotrexate withdrawal compared to standard supportive care. These findings support the routine application of comprehensive correction protocols to enhance methotrexate tolerability and ensure more consistent disease control in rheumatoid polyarthritis patients.